Anticancer Drug Development
eBook - ePub

Anticancer Drug Development

  1. 397 pages
  2. English
  3. ePUB (mobile friendly)
  4. Available on iOS & Android
eBook - ePub

Anticancer Drug Development

About this book

Here in a single source is a complete spectrum of ideas on the development of new anticancer drugs. Containing concise reviews of multidisciplinary fields of research, this book offers a wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death. Detailed descriptions of sources for new drugs and methods for testing and clinical trial design are also provided.- One work that can be consulted for all aspects of anticancer drug development- Concise reviews of research fields, combined with practical scientific detail, written by internationally respected experts- A wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death- Detailed descriptions of the sources of new anticancer drugs, including combinatorial chemistry, phage display, and natural products- Discussion of how new drugs can be tested in preclinical systems, including the latest technology of robotic assay systems, cell culture, and experimental animal techniques- Hundreds of references that allow the reader to access relevant scientific and medical literature- Clear illustrations, some in color, that provide both understanding of the field and material for teaching

Frequently asked questions

Yes, you can cancel anytime from the Subscription tab in your account settings on the Perlego website. Your subscription will stay active until the end of your current billing period. Learn how to cancel your subscription.
At the moment all of our mobile-responsive ePub books are available to download via the app. Most of our PDFs are also available to download and we're working on making the final remaining ones downloadable now. Learn more here.
Perlego offers two plans: Essential and Complete
  • Essential is ideal for learners and professionals who enjoy exploring a wide range of subjects. Access the Essential Library with 800,000+ trusted titles and best-sellers across business, personal growth, and the humanities. Includes unlimited reading time and Standard Read Aloud voice.
  • Complete: Perfect for advanced learners and researchers needing full, unrestricted access. Unlock 1.4M+ books across hundreds of subjects, including academic and specialized titles. The Complete Plan also includes advanced features like Premium Read Aloud and Research Assistant.
Both plans are available with monthly, semester, or annual billing cycles.
We are an online textbook subscription service, where you can get access to an entire online library for less than the price of a single book per month. With over 1 million books across 1000+ topics, we’ve got you covered! Learn more here.
Look out for the read-aloud symbol on your next book to see if you can listen to it. The read-aloud tool reads text aloud for you, highlighting the text as it is being read. You can pause it, speed it up and slow it down. Learn more here.
Yes! You can use the Perlego app on both iOS or Android devices to read anytime, anywhere — even offline. Perfect for commutes or when you’re on the go.
Please note we cannot support devices running on iOS 13 and Android 7 or earlier. Learn more about using the app.
Yes, you can access Anticancer Drug Development by Bruce C. Baguley,David J. Kerr in PDF and/or ePUB format, as well as other popular books in Medicine & Oncology. We have over one million books available in our catalogue for you to explore.

Information

Publisher
Academic Press
Year
2001
Print ISBN
9780120726516
eBook ISBN
9780080490441
Topic
Medicine
Subtopic
Oncology

Table of contents

  1. Cover image
  2. Title page
  3. Table of Contents
  4. Copyright
  5. CONTRIBUTORS
  6. PREFACE
  7. Chapter 1: A BRIEF HISTORY OF CANCER CHEMOTHERAPY
  8. Chapter 2: NOVEL TARGETS IN THE CELL CYCLE AND CELL CYCLE CHECKPOINTS
  9. Chapter 3: GROWTH FACTOR AND SIGNAL TRANSDUCTION TARGETS FOR CANCER THERAPY
  10. Chapter 4: CELL DEATH PATHWAYS AS TARGETS FOR ANTICANCER DRUGS
  11. Chapter 5: DRUG RESISTANCE PATHWAYS AS TARGETS
  12. Chapter 6: ROLE OF MATRIX METALLOPROTEINASES AND PLASMINOGEN ACTIVATORS IN CANCER INVASION AND METASTASIS: THERAPEUTIC STRATEGIES
  13. Chapter 7: TUMOR VASCULATURE AS A TARGET
  14. Chapter 8: GENE-DIRECTED ENZYME PRODRUG THERAPY
  15. Chapter 9: TUMOR ANTIGENS AS TARGETS FOR ANTICANCER DRUG DEVELOPMENT
  16. Chapter 10: STRUCTURE-BASED DRUG DESIGN AND ITS CONTRIBUTIONS TO CANCER CHEMOTHERAPY
  17. Chapter 11: THE CONTRIBUTION OF SYNTHETIC ORGANIC CHEMISTRY TO ANTICANCER DRUG DEVELOPMENT
  18. Chapter 12: BIOSYNTHETIC PRODUCTS FOR ANTICANCER DRUG DESIGN AND TREATMENT: THE BRYOSTATINS
  19. Chapter 13: DNA-ENCODED PEPTIDE LIBRARIES AND DRUG DISCOVERY
  20. Chapter 14: MECHANISM-BASED HIGH-THROUGHPUT SCREENING FOR NOVEL ANTICANCER DRUG DISCOVERY
  21. Chapter 15: TUMOR CELL CULTURES IN DRUG DEVELOPMENT
  22. Chapter 16: SCREENING USING ANIMAL SYSTEMS
  23. Chapter 17: RELEVANCE OF PRECLINICAL PHARMACOLOGY AND TOXICOLOGY TO PHASE I TRIAL EXTRAPOLATION TECHNIQUES: RELEVANCE OF ANIMAL TOXICOLOGY
  24. Chapter 18: CLINICAL TRIAL DESIGN: INCORPORATION OF PHARMACOKINETIC, PHARMACODYNAMIC, AND PHARMACOGENETIC PRINCIPLES
  25. Chapter 19: TUMOR IMAGING APPLICATIONS IN THE TESTING OF NEW DRUGS
  26. Chapter 20: MECHANISTIC APPROACHES TO PHASE I CLINICAL TRIALS
  27. INDEX